Extended Data Table 1 Baseline characteristics of patients with GC/GEJ cancer who received satri-cel monotherapy

From: Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

Patient with GC/GEJ cancer

Dose-escalation/de-escalation (n = 12)

Dose expansion (n = 47)

Total (n = 59)

Cohort 1 (n = 40)

Cohort 3 (n = 5)

Cohort 4 (n = 2)

Median age (range), year

54.5 (38–69)

44.0 (25–69)

50.0 (30–55)

50.0 (39–61)

48.0 (25–69)

Male, n (%)

9 (75.0)

19 (47.5)

1 (20.0)

1 (50.0)

30 (50.8)

ECOG, n (%)

 0

1 (8.3)

2 (5.0)

1 (20.0)

1 (50.0)

5 (8.5)

 1

11 (91.7)

38 (95.0)

4 (80.0)

1 (50.0)

54 (91.5)

Histological (Lauren) classification, n (%)

 Intestinal type

5 (41.7)

6 (15.0)

0

2 (100)

13 (22.0)

 Diffuse type

3 (25.0)

20 (50.0)

3 (60.0)

0

26 (44.1)

 Mixed type

3 (25.0)

8 (20.0)

1 (20.0)

0

12 (20.3)

 Unknown

1 (8.3)

6 (15.0)

1 (20.0)

0

8 (13.6)

CLDN18.2 expression, n (%)a

 Low expression

 

2 (5.0)

0

0

2 (3.4)

 Medium/high expression

12 (100)

38 (95.0)

5 (100)

2 (100)

57 (96.6)

No. of previous lines, n (%)

 1

1 (8.3)

16 (40.0)

5 (100)

0

26 (44.1)

 2

8 (66.7)

18 (45.0)

0

0

22 (37.3)

 ≥3

3 (25.0)

6 (15.0)

0

2 (100)

11 (18.6)

Previous systemic therapies, n (%)

 Fluorouracil/analogs and derivatives

12 (100)

40 (100)

5 (100)

2 (100)

59 (100)

 Taxanes

10 (83.3)

29 (72.5)

3 (60.0)

1 (50.0)

43 (72.9)

 Platinum

12 (100)

36 (90.0)

4 (80.0)

2 (100)

54 (91.5)

 Anti-PD-1/PD-L1 antibody

5 (41.7)

14 (35.0)

1 (20.0)

0

20 (33.9)

 Polykinase inhibitorb

4 (33.3)

7 (17.5)

0

0

11 (18.6)

Median no. of metastatic organs, n (%)

 ≤2

5 (41.7)

21 (52.5)

5 (100)

1 (50.0)

32 (54.2)

 ≥3

7 (58.3)

19 (47.5)

0

1 (50.0)

27 (45.8)

Metastatic organs, n (%)

 Liver

5 (41.7)

6 (15.0)

0

1 (50.0)

12 (20.3)

 Lung

4 (33.3)

4 (10.0)

0

1 (50.0)

9 (15.3)

 Peritoneal

9 (75.0)

33 (82.5)

4 (80.0)

1 (50.0)

47 (79.7)

 Bone

2 (16.7)

6 (15.0)

0

0

8 (13.6)

 Distant lymph node

5 (41.7)

17 (42.5)

1 (20.0)

0

23 (39.0)

  1. a CLDN18.2 expression level by IHC staining intensity was graded as 1+, 2+ or 3+ and multiplied by the percentage of cells that were positive. Low expression was defined as any intensity with a percentage of less than 40% or intensity 1+ with any percentage; medium expression was defined as intensity 2+ or 3+ with a percentage of 40% (inclusive) to 69%; high expression was defined as intensity 2+ or 3+ with a percentage of 70% or higher.
  2. b Polykinase inhibitor: multi-target tyrosine kinase inhibitor, including apatinib, anlotinib, etc.
Back to article page